TNF Inhibitor denied as not medically necessary by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors for Medical Necessity

A medical-necessity denial from Anthem Blue Cross means the plan's clinical reviewer determined that the documentation submitted did not demonstrate that a TNF inhibitor meets the criteria set out in Anthem's applicable medical/coverage policy. Common reasons include: inadequate documentation of conventional therapy failure, insufficient evidence of disease severity, missing specialist involvement, or a mismatch between the diagnosis code and the policy's covered indications.

This is one of the most successfully appealed denial types. Medical-necessity criteria are defined by policy language, and a well-organized appeal that maps each policy requirement to a specific chart fact — rather than a general clinical argument — is far more likely to succeed.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You are entitled to a full-and-fair review. Request the specific clinical criteria and the qualifications of the reviewer. Submit a written appeal with supporting clinical documentation within the timeframe on your denial letter.
• External independent review: Available after internal exhaustion on ACA-compliant plans. The window is generally up to approximately four months from the final internal denial. An IRO's decision is binding on Anthem.
• Expedited review: If waiting for a standard decision would seriously jeopardize your health, request expedited review in writing at the same time as your internal appeal.

## Documentation to Gather

1. Diagnosis confirmation — specialist evaluation notes, relevant lab or imaging findings, and ICD codes that precisely match the covered indication in Anthem's policy. 2. Conventional therapy history — for each prior agent required by Anthem's step-therapy policy, document the drug name, start date, stop date, dose adjustment history (per chart), and reason for discontinuation (inadequate response or intolerance). 3. Disease severity — recent office notes, validated disease-activity instruments, or objective clinical findings that place the patient in the severity tier Anthem's policy requires for biologic initiation. 4. Specialist involvement — documentation of care by the appropriate specialist (rheumatologist, gastroenterologist, dermatologist, etc.) as required by the policy. 5. Prescriber medical-necessity letter — a detailed letter addressing each Anthem policy criterion by name and providing a specific chart-based answer for each.

## Criteria-Mapping Structure

Anthem's medical-necessity determination follows its published criteria. Build your response as a table:

| Anthem Policy Criterion | Chart-Based Answer | |---|---| | [Copy each criterion word-for-word from Anthem's policy] | [Note date, clinician name, and exact finding from the chart that satisfies it] |

Your prescriber's letter should: - Reference the FDA-approved prescribing information for the specific TNF inhibitor - Cite the applicable guideline organization (e.g., ACR, AGA, AAD) and its recommendation for your diagnosis - Explain why the prior therapy failures documented in the chart satisfy Anthem's step requirements

Do not rely on any specific numeric thresholds, eligibility cutoffs, or dosing details from memory. Confirm all clinical criteria against the current FDA prescribing label and Anthem's current published medical/coverage policy.